Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain 5 Colorectal Neoplasms 5 Neoplasms 4 Breast Neoplasms 4 Stomatitis 3 Neoplasm Metastasis 3 Adenoma 3 Urologic Neoplasms 2 Stomach Neoplasms 2 Mucositis 2 Insulin Resistance 2 Head and Neck Neoplasms 2 Vulvodynia 1 Urologic Diseases 1 Urolithiasis 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Sleep Initiation and Maintenance Disorders 1 Skin Neoplasms 1 Rectal Neoplasms 1 Polycystic Ovary Syndrome 1 Pain, Postoperative 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Mobility Limitation 1 Melanoma 1 MRSA Colonization 1

Interventions

Dexamethasone 808 Bortezomib 446 Lenalidomide 430 Cyclophosphamide 336 Melphalan 250 Calcium Dobesilate 236 daratumumab 217 pomalidomide 201 carfilzomib 181 fludarabine phosphate 131 Thalidomide 121 fludarabine 118 Peripheral Blood Stem Cell Transplantation 117 Filgrastim 111 ixazomib 85 Mycophenolic Acid 85 Granulocyte Colony-Stimulating Factor 84 Busulfan 83 Whole-Body Irradiation 80 Tacrolimus 75 dexamethasone acetate 74 Cyclosporine 67 Prednisone 64 dexamethasone 21-phosphate 63 isatuximab 62 elotuzumab 60 auricularum 57 Antilymphocyte Serum 55 belantamab mafodotin 54 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Water × Clear all

NCT00970021 2014-02-25

Agaricus Blazei Murill in Patients With Multiple Myeloma

Oslo University Hospital

Phase 2 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡